NeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership with Quazar Investment
NeOnc Technologies (NASDAQ: NTHI) has secured board approval for a strategic $50 million partnership with Quazar Investment. The board unanimously approved the company's participation in the equity investment and MENA region expansion on June 30, 2025, marking the first of five required milestones.
The proposed structure includes a $25 per share pricing, with 70% of proceeds allocated to NeOnc common stock acquisition and 30% dedicated to clinical trials and infrastructure development in the UAE and MENA region. The company must complete remaining conditions within 120 days, including establishing NuroMENA and NuroCure in Abu Dhabi, executing licensing agreements for NEO100 and NEO212, and finalizing offering documents and business plans.
NeOnc Technologies (NASDAQ: NTHI) ha ottenuto l'approvazione del consiglio per una partnership strategica da 50 milioni di dollari con Quazar Investment. Il consiglio ha approvato all'unanimit脿 la partecipazione dell'azienda all'investimento azionario e all'espansione nella regione MENA il 30 giugno 2025, segnando il primo di cinque traguardi necessari.
La struttura proposta prevede un prezzo di 25 dollari per azione, con il 70% dei proventi destinato all'acquisto di azioni ordinarie NeOnc e il 30% dedicato a studi clinici e sviluppo infrastrutturale negli Emirati Arabi Uniti e nella regione MENA. L'azienda deve completare le condizioni rimanenti entro 120 giorni, inclusa la creazione di NuroMENA e NuroCure ad Abu Dhabi, la stipula di accordi di licenza per NEO100 e NEO212 e la finalizzazione dei documenti dell'offerta e dei piani aziendali.
NeOnc Technologies (NASDAQ: NTHI) ha obtenido la aprobaci贸n del consejo para una asociaci贸n estrat茅gica de 50 millones de d贸lares con Quazar Investment. El consejo aprob贸 por unanimidad la participaci贸n de la empresa en la inversi贸n de capital y la expansi贸n en la regi贸n MENA el 30 de junio de 2025, marcando el primero de cinco hitos requeridos.
La estructura propuesta incluye un precio de 25 d贸lares por acci贸n, con el 70% de los ingresos destinados a la adquisici贸n de acciones comunes de NeOnc y el 30% dedicado a ensayos cl铆nicos y desarrollo de infraestructura en los EAU y la regi贸n MENA. La empresa debe completar las condiciones restantes en 120 d铆as, incluyendo el establecimiento de NuroMENA y NuroCure en Abu Dhabi, la ejecuci贸n de acuerdos de licencia para NEO100 y NEO212, y la finalizaci贸n de documentos de oferta y planes de negocio.
NeOnc Technologies (NASDAQ: NTHI)電� Quazar Investment鞕�鞚� 鞝勲灥鞝� 5,000毵� 雼煬 韺岉姼雱堨嫮鞐� 雽�頃� 鞚挫偓須岇潣 鞀轨澑鞚� 氚涭晿鞀惦媹雼�. 鞚挫偓須岆姅 2025雲� 6鞗� 30鞚� 須岇偓鞚� 歆�攵� 韴瀽 彀胳棳 氚� MENA 歆�鞐� 頇曥灔鞐� 雽�頃� 毵岇灔鞚检箻搿� 鞀轨澑頄堨溂氅�, 鞚措姅 雼れ劘 臧滌潣 頃勳垬 鞚挫爼響� 欷� 觳� 氩堨Ц鞛呺媹雼�.
鞝滌晥霅� 甑“電� 欤茧嫻 25雼煬 臧�瓴╈潉 韽暔頃橂┌, 靾橃澋鞚� 70%電� NeOnc 氤错喌欤� 毵れ瀰鞐�, 30%電� UAE 氚� MENA 歆�鞐棎靹� 鞛勳儊 鞁滍棙瓿� 鞚疙攧霛� 臧滊皽鞐� 頃犽嫻霅╇媹雼�. 須岇偓電� 120鞚� 鞚措偞鞐� NuroMENA 氚� NuroCure毳� 鞎勲秬雼る箘鞐� 靹る頃橁碃, NEO100 氚� NEO212鞐� 雽�頃� 霛检澊靹犾姢 瓿勳暯鞚� 觳搓舶頃橂┌, 瓿惦 氍胳劀 氚� 靷梾 瓿勴殟鞚� 鞕勲頃橂姅 霌� 雮潃 臁瓣贝霌れ潉 於╈”頃挫暭 頃╇媹雼�.
NeOnc Technologies (NASDAQ : NTHI) a obtenu l'approbation du conseil d'administration pour un partenariat strat茅gique de 50 millions de dollars avec Quazar Investment. Le conseil a approuv茅 脿 l'unanimit茅 la participation de l'entreprise 脿 l'investissement en actions et 脿 l'expansion dans la r茅gion MENA le 30 juin 2025, marquant ainsi le premier des cinq jalons requis.
La structure propos茅e comprend un prix de 25 dollars par action, avec 70 % des fonds allou茅s 脿 l'acquisition d'actions ordinaires NeOnc et 30 % d茅di茅s aux essais cliniques et au d茅veloppement des infrastructures aux 脡mirats arabes unis et dans la r茅gion MENA. L'entreprise doit remplir les conditions restantes dans un d茅lai de 120 jours, notamment la cr茅ation de NuroMENA et NuroCure 脿 Abou Dhabi, la conclusion d'accords de licence pour NEO100 et NEO212, ainsi que la finalisation des documents d'offre et des plans d'affaires.
NeOnc Technologies (NASDAQ: NTHI) hat die Zustimmung des Vorstands f眉r eine strategische Partnerschaft in H枚he von 50 Millionen US-Dollar mit Quazar Investment erhalten. Der Vorstand genehmigte am 30. Juni 2025 einstimmig die Beteiligung des Unternehmens an der Eigenkapitalinvestition und der Expansion in der MENA-Region, was den ersten von f眉nf erforderlichen Meilensteinen darstellt.
Die vorgeschlagene Struktur sieht einen Preis von 25 US-Dollar pro Aktie vor, wobei 70 % der Erl枚se f眉r den Erwerb von NeOnc-Stammaktien und 30 % f眉r klinische Studien und den Ausbau der Infrastruktur in den VAE und der MENA-Region verwendet werden. Das Unternehmen muss die verbleibenden Bedingungen innerhalb von 120 Tagen erf眉llen, darunter die Gr眉ndung von NuroMENA und NuroCure in Abu Dhabi, den Abschluss von Lizenzvereinbarungen f眉r NEO100 und NEO212 sowie die Fertigstellung der Angebotsunterlagen und Gesch盲ftspl盲ne.
- Strategic $50 million investment commitment at $25 per share
- Geographic expansion into MENA region through new operational infrastructure
- Unanimous board approval signals strong internal support
- Development acceleration potential for core assets NEO100 and NEO212
- Transaction remains subject to multiple closing conditions within 120-day deadline
- Current agreement is based on non-binding term sheet
- Potential share dilution from new stock issuance
- Significant operational and regulatory hurdles in new geographic expansion
Insights
NeOnc's board approval advances $50M Quazar deal, providing needed capital for clinical development and MENA expansion.
This milestone represents tangible progress in NeOnc's strategic partnership with Quazar Investment, though it's merely the first step in a five-milestone closing process. The proposed
The transaction structure reveals a sophisticated approach to global expansion while maintaining core asset development. The company must clear four remaining hurdles within 120 days, including forming Abu Dhabi entities (NuroMENA and NuroCure), executing sub-license agreements for key therapeutics (NEO100 and NEO212), finalizing legal documentation, and securing approval for a comprehensive business plan.
This deal addresses a critical challenge for clinical-stage biotechs 鈥� securing sufficient funding to advance therapeutics through expensive clinical trials. The
CALABASAS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has achieved a key milestone toward closing its previously announced strategic transaction with Quazar Investment: formal approval from NeOnc鈥檚 Board of Directors.
On June 30, 2025, NeOnc鈥檚 Board unanimously approved the company鈥檚 participation in the contemplated
鈥淲e are excited to report tangible progress in advancing our strategic partnership with Quazar Investment,鈥� said Amir Heshmatpour, Executive Chairman & President of NeOnc Technologies Holdings, Inc. 鈥淭he Board鈥檚 full support validates our shared vision for establishing a strong operational presence in the MENA region and accelerating clinical development of our core assets.鈥�
Under the non-binding term sheet, Quazar intends to lead a capital formation round of up to
To complete the transaction, NeOnc must satisfy the remaining conditions within 120 days, including:
- Legal formation of NuroMENA and NuroCure in Abu Dhabi.
- Execution and transfer of a Sub-License Agreement from NeOnc to NuroCure, covering NEO100 and NEO212, pursuant to NeOnc鈥檚 license from USC Stevens Center for Innovation.
- Finalization of offering documents, including subscription agreements and a shareholder agreement.
- Approval of a comprehensive two-year business plan and budget, outlining operational and clinical milestones.
The closing remains subject to these conditions and the successful completion of the capital formation process.
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company鈥檚 NEO鈩� drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc鈥檚 NEO100鈩� and NEO212鈩� therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit聽.
Important Cautions Regarding Forward Looking Statements
This press release contains 鈥渇orward-looking statements鈥� within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� 鈥渋ntend,鈥� 鈥渆xpect,鈥� 鈥減lan,鈥� 鈥渂udget,鈥� 鈥渇orecast,鈥� 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渆stimate,鈥� 鈥減redict,鈥� 鈥減otential,鈥� 鈥渃ontinue,鈥� 鈥渆valuating,鈥� or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.
Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.
The 鈥淩isk Factors鈥� section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
鈥淣EO100鈥� and NEO 鈥�212鈥� are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:鈥ㄢ��
Investor Contact:鈥ㄢ��
James Carbonara鈥�
Hayden IR鈥�
(646)-755-7412鈥�
FAQ
What is the value and share price of Quazar Investment's strategic partnership with NeOnc Technologies (NTHI)?
How will the $50 million investment in NeOnc Technologies (NTHI) be allocated?
What conditions must NeOnc Technologies (NTHI) meet to close the Quazar Investment deal?
What therapeutic areas does NeOnc Technologies (NTHI) focus on?
When did NeOnc Technologies' (NTHI) board approve the Quazar Investment partnership?
